iifl-logo

Mankind Pharma Ltd Half Yearly Results

2,550.6
(-0.71%)
Sep 5, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Sept-2024Mar-2024Sept-2023Mar-2023

Gross Sales

6,237.51

5,969.93

4,973.72

5,286.72

4,143.6

Excise Duty

0

0

0

0

0

Net Sales

6,237.51

5,969.93

4,973.72

5,286.72

4,143.6

Other Operating Income

0

0

0

0

0

Other Income

337.05

216.51

169.61

126.8

89.78

Total Income

6,574.56

6,186.44

5,143.33

5,413.52

4,233.38

Total Expenditure

4,751.38

4,438.13

3,797.5

3,949.26

3,289.88

PBIDT

1,823.18

1,748.31

1,345.83

1,464.26

943.51

Interest

411.4

18.01

17.79

14.96

17.92

PBDT

1,411.78

1,730.3

1,328.04

1,449.3

925.59

Depreciation

407.86

213.36

194.58

183.84

169.31

Minority Interest Before NP

0

0

0

0

0

Tax

289.21

306.83

185.65

306.86

166.01

Deferred Tax

-94.46

8.16

11.41

-46.77

0.85

Reported Profit After Tax

809.17

1,201.95

936.4

1,005.37

589.42

Minority Interest After NP

8.17

11.99

11.4

17.47

19.83

Net Profit after Minority Interest

801

1,189.96

925

987.9

569.59

Extra-ordinary Items

4.53

0

0.98

0

0

Adjusted Profit After Extra-ordinary item

796.47

1,189.96

924.02

987.9

569.59

EPS (Unit Curr.)

19.41

29.7

23.09

24.66

14.22

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

41.26

40.06

40.06

40.06

40.06

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

29.22

29.28

27.05

27.69

22.77

PBDTM(%)

-

-

-

-

-

PATM(%)

12.97

20.13

18.82

19.01

14.22

Mankind Pharma: Related NEWS

Mankind Pharma Q1 Updates: Net profit down ~18%

The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.

1 Aug 2025|01:41 PM
Read More
Top Stocks for Today - 01st August 2025

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

1 Aug 2025|08:58 AM
Read More
Mankind Pharma posts mixed performance in Q4; stock slips ~4%

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.

22 May 2025|12:15 PM
Read More
Top Stocks for Today - 22nd May 2025

Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.

22 May 2025|06:38 AM
Read More
Mankind Pharma Faces ₹183.11 Crore Tax Demand

The cumulative demand, including interest charges, is ₹183.11 crore.

30 Mar 2025|04:34 PM
Read More
Mankind Pharma Merges Three Subsidiaries

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

30 Mar 2025|01:33 PM
Read More
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

28 Feb 2025|11:13 PM
Read More
Top Stocks for Today - 24th January 2025

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

24 Jan 2025|07:50 AM
Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

23 Jan 2025|11:57 PM
Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

8 Jan 2025|04:01 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.